Skip to main content
SpringerLink
Log in

Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed as cost per life-years gained.

Design: A decision-analytic model, using Markov process techniques, was designed to evaluate the lifetime clinical and economic consequences of treatment with letrozole compared with standard care with megestrol. Themodel was based on clinical trial results showing a clear advantage of letrozole in terms of time to progression and duration of response.

Setting: The setting of the study was that of the UK healthcare system in 1996.

Patients and participants: A hypothetical cohort of patients, identical to the patients recruited for the AR/BC2 clinical trial,whowere postmenopausal women with advanced breast cancer who had previously failed to respond to first-line or adjuvant anti-estrogen therapy.

Interventions: The dosages of medications were 2.5 and 160 mg/day for letrozole and megestrol, respectively. The analysis covered the period from treatment initiation until death (lifetime model). Effectiveness was expressed as survival and time without progression, and the model also included all relevant economic measures.

Main outcome measures and results: Based on the model, the average survival time of the letrozole group was 2.1 years (25.3 months) versus 1.9 years (21.5 months) for the megestrol group, a gain in survival of 2.4 months (10.5%). The average time without progression, cumulatively calculated over the different treatment options, amounted to 20.2 months for letrozole and 17.8 months for megestrol, an increase of 13.7% for the former patients. The total average cost per patient for the treatment of advanced breast cancer starting from second-line hormone therapy until death was higher in the letrozole group at £7547 versus £6820 for the megestrol group (discounted at an annual rate of 5%), leading to an incremental cost-effectiveness ratio of £3588 per life-year gained (1996 values).

Conclusions: Based on the assumptions used in this model, letrozole offers a suitable alternative tomegestrol in the treatment of second-line hormone therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Levi F, La Vecchia C, Lucchini F, et al. Cancer mortality in Europe, 1990–1992. Eur J Cancer Prev 1995; 4 (5): 389–417

    Article  PubMed  CAS  Google Scholar 

  2. Jones AL, Smith IE. Medical treatment of breast cancer, 1993

    Google Scholar 

  3. Cancer Research Campaign (CRC). Factsheet no. 7. London: CRC, 1991

    Google Scholar 

  4. Butler JR, Furnival CM, Hart RF. The cost of treating breast cancer in Australia and the implications for breast cancer screening. Aust NZ J Surg 1995; 65 (7): 485–91

    Article  CAS  Google Scholar 

  5. Elixhauser A. Cost of advanced breast cancer and the cost effectiveness of advanced breast cancer screening. Int J Technol Assess Health Care 1991; 7: 604–15

    Article  PubMed  CAS  Google Scholar 

  6. Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of advanced breast cancer and lung cancer. Med Care 1991; 29: 40–9

    Article  PubMed  CAS  Google Scholar 

  7. Epstein RJ. Does the advanced breast cancer dollar make sense? Eur J Cancer 1992; 28: 486–91

    Article  PubMed  CAS  Google Scholar 

  8. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856–60

    Article  PubMed  CAS  Google Scholar 

  9. Hurley SF, Huggins RM, Snyder HD, et al. The cost of breast cancer recurrences. Br J Cancer 1992; 65: 449–55

    Article  PubMed  CAS  Google Scholar 

  10. De Koning HJ, van Ineveld BM, de Haes JCJM, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992; 65: 950–5

    Article  PubMed  Google Scholar 

  11. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 Suppl. 4: 17–28

    Article  PubMed  Google Scholar 

  12. Leonard RCF. Metastatic breast cancer. BMJ 1994; 309: 1501–3

    Article  PubMed  CAS  Google Scholar 

  13. Corry JF, Lonning PE. Systematic therapy in advanced breast cancer: efficacy and cost-utility. Pharmacoeconomics 1994; 5: 190–212

    Article  Google Scholar 

  14. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721–8

    Article  PubMed  CAS  Google Scholar 

  15. Santen RJ, Manni A, Harvey H, et al. Endocrine treatment of breast cancer in women. Endocr Rev 1990; 11: 221–65

    Article  PubMed  CAS  Google Scholar 

  16. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: doubleblind randomised trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998: 16 (2): 453–61

    PubMed  CAS  Google Scholar 

  17. Nuijten MJC, Fitzimon C, Waild F, et al. Economic evaluation of letrozole in the treatment of advanced breast cancer in post-menopausal women in Canada. Value in Health. In press

  18. Weinstein M, Fineberg H. Clinical decision analysis. London: W. B. Saunders Company, 1980

    Google Scholar 

  19. Holloway CA. Decision making under uncertainty models and choices. Englewood Cliffs (NJ): Prentice Hall Inc., 1979

    Google Scholar 

  20. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 1: 52–8

    Article  Google Scholar 

  21. Garcia-Giralt E, Ayme Y, Carton M, et al. Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Res Treat 1992; 24: 139–45

    Article  PubMed  CAS  Google Scholar 

  22. Brufman G, Isacson R, Haim N, et al. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Oncology 1994; 51 (3): 258–61

    Article  PubMed  CAS  Google Scholar 

  23. Iveson TJ, Ahern J, Smith TE. Response to third-line endocrine treatment for advanced breast cancer. Eur J Cancer 1993; 29A (4): 572–4

    Article  Google Scholar 

  24. Ingle JN, Johnson PA, Suman VJ, et al. A randomised phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997; 80 (2): 218–24

    Article  PubMed  CAS  Google Scholar 

  25. Alonso MC, Tabernero JM, Ojeda B, et al. Aphase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 1995; 34 (1): 15–24

    Article  PubMed  CAS  Google Scholar 

  26. Fraser SCA, Dobbs HJ, Ebbs SR, et al. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer 1993; 67: 402–6

    Article  PubMed  CAS  Google Scholar 

  27. Viladiu P, Alonso MC, Avella A, et al. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. Cancer 1985; 56: 2745–50

    Article  PubMed  CAS  Google Scholar 

  28. Mouridsen HT, Rose C, Engelsmann E, et al. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. J Steroid Biochem 1985; 23 (6B): 1141–6

    Article  PubMed  CAS  Google Scholar 

  29. Hoogstraten B, Gad-el-Mawla N, Maloney TR, et al. Combined modality therapy for first recurrence of breast cancer. Cancer 1984; 54: 2248–56

    Article  PubMed  CAS  Google Scholar 

  30. Gerritsen M, Wagener DJ, Schade RW, Breast Cancer Study Group, et al. Palliative chemotherapy with CMF after the same adjuvant regimen for breast cancer. Neth J Med 1995; 46 (3): 131–5

    Article  PubMed  CAS  Google Scholar 

  31. Gregory WM, Smith P, Richards MA, et al. Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 1993; 68 (5): 988–95

    Article  PubMed  CAS  Google Scholar 

  32. Petru E, Schmähl. On the relevance of ’second-line’ cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschr 1986; 23: 790–7

    Google Scholar 

  33. Fink A, Kosecoff J, Chassin M, et al. Consensusmethods: characteristics and guidelines for use. Am J Public Health 1984; 9: 979–83

    Article  Google Scholar 

  34. Jariath N, Weinstein J. The Delphi methodology (Pt 2): a useful administrative approach. Cand J Nurs Adm 1994; 7 (4): 7–20

    Google Scholar 

  35. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 376–80

    Article  PubMed  CAS  Google Scholar 

  36. Hutton J, Brown R, Borowitz M, et al. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996; 9 Suppl. 2: 8–22

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MEDTAP, Amsterdam, The Netherlands

    Mark Nuijten

  2. Medical Decision Making Department, Erasmus University, Rotterdam, The Netherlands

    Liebeth Meester

  3. Novartis Pharma AG, Basle, Switzerland

    Franz Waibel & Suzanne Wait

Authors
  1. Mark Nuijten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liebeth Meester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franz Waibel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suzanne Wait
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Nuijten.

Additional information

Work conducted while an employee at Benefit B. V., Leiden, The Netherlands

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nuijten, M., Meester, L., Waibel, F. et al. Cost Effectiveness of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in the UK. Pharmacoeconomics 16, 379–397 (1999). https://doi.org/10.2165/00019053-199916040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916040-00006

Keywords

Search

Navigation